Oramed Pharmaceuticals (NASDAQ: ORMP) has developed an innovative technology to transform injectable treatments into oral therapies. Its flagship product, an oral insulin capsule, has the potential to better the lives of millions of diabetics around the world – allowing type 2 patients to begin insulin therapy without fear of needles. Oramed’s oral insulin is currently in advanced clinical trials under the US FDA for both type 1 and type 2 diabetes.
- YuanMing Capital
- Terralab Ventures